GLP-1 drugs may be transforming obesity and diabetes care, but for many patients, the benefits come with a cost: persistent nausea and vomiting. These side effects remain one of the top reasons people discontinue treatment. That’s why the results of a recent Phase 2 trial for NG101—a peripherally acting D2 antagonist—deserve attention. A New Approach…
Every time a new observational data point appears, the reaction is the same: Instant celebration. Instant amplification. Zero skepticism. Doctors should be the guardrails in moments like this. Instead, many are becoming megaphones for half-baked narratives that generate attention but not accuracy. GLP-1s are already drowning in hype.Weight loss! Heart benefits! Now, anti-cancer powers? Except…
Every few weeks, a new headline seems to push GLP-1 drugs—Semaglutide and Tirzepatide—deeper into “miracle drug” territory. Weight loss. Heart benefits. Reduced inflammation. Better metabolic markers. And now… longer survival for colon cancer patients? A recently circulated data point claims that colon cancer patients using Semaglutide or Tirzepatide were less than half as likely to die within…
Pharma sees GLP-1 receptor agonists as a way to make huge profits. Once developed for Type 2 diabetes, they’ve evolved into the hottest category in weight management. The numbers are hard to ignore — real, measurable weight loss, improved metabolic profiles, and hints of cardiovascular benefit. In pharma, it’s rare when science, consumer interest, and…
There’s a seductive simplicity to it, isn’t there? Skip the messy bureaucracy, forget the government programs, and hand people cash to buy their own health insurance. Personal responsibility! Consumer choice! Market efficiency! It sounds so clean, so American, so obvious. It’s also spectacularly, dangerously wrong. I’m tired of watching this zombie idea stumble through policy debates,…
The (DTC) marketing landscape is undergoing a profound transformation. As patients become more empowered in their healthcare decisions and regulatory scrutiny intensifies, pharma marketers face a critical challenge: delivering the right message to the right patient at the right time while maintaining compliance and trust. Artificial intelligence is emerging as a game-changing solution to this…
There are moments when we must set aside our political jerseys and acknowledge a simple, uncomfortable truth: when healthcare premiums rise beyond reach for those already struggling, something fundamental has broken in our social contract. I don’t care if you’re a Democrat, Republican, Libertarian, or entirely unaffiliated. I don’t care if you believe in universal…
The FDA occupies a unique and pivotal role: as regulator of new medicines, it must ensure therapies are safe and effective—but also that they reach patients in need without undue delay. Today, the agency is under growing scrutiny. Recent leadership upheaval and regulatory reversals—especially a sharp turn in the case of uniQure N.V.’s gene-therapy for…
The weight loss drug Gold Rush has entered a new phase. As major telehealth companies scramble to maintain their grip on the lucrative GLP-1 market, they’ve found a creative workaround: “microdosing.” Noom, Found, and Hims & Hers have all recently launched programs offering lower doses of semaglutide and tirzepatide, marketing them as gentler alternatives with…
There’s no question that GLP-1 medications have captured the public’s imagination. Once seen as niche diabetes drugs, they’re now among the most talked-about treatments in the world, thanks to their weight-loss potential and celebrity endorsements. As prices begin to come down, many analysts are predicting another sales surge. But from a strategic standpoint, it’s unlikely…